Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Celecoxib safe for short-term use in patients with cirrhosis

23.02.2005


Naproxen harms renal function after short-term use in cirrhotic patients



Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study. The findings are published in the March 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., the journal is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

Previous studies in experimental cirrhosis have shown that selective COX-2 inhibitors, such as celecoxib, do not affect renal function. By contrast, nonsteroidal anti-inflammatory drugs, including naproxen, have long been associated with acute renal failure in cirrhotic patients. To further investigate these findings, researchers, led by Joan Clària of Barcelona’s Hospital Clinic, sought to compare the effects of celecoxib, naproxen and a placebo on cirrhotic patients.


They recruited 28 patients who had cirrhosis and ascites and increased activity of the renin-angiotensin system. Each one was randomly assigned to a short-term course (5 doses over 60 hours) of celecoxib, naproxen or a placebo. Results from ten of the participants were not considered in the analysis due to the discovery of hepatorenal syndrome, or lack of stable serum concentrations of clearance substances needed to calculate glomerular filtration rate (GFR) and renal plasma flow (RPF.) For the remaining patients, the researchers measured and monitored platelet and renal function, as well as the diuretic and natriuretic responses to furosemide.

Celecoxib, like the placebo, did not inhibit platelet aggregation or thromboxane B2 synthesis, while naproxen did. Celecoxib also did not affect renal function, according to RPF, GFR and serum creatinine values, while naproxen reduced both RPF and GFR and increased serum creatinine levels. Neither celecoxib nor the placebo affected the diuretic or natriuretic effects of furosemide or the urinary excretion of prostaglandins. Naproxen significantly reduced both the diuretic and natriuretic responses to furosemide. Interestingly, both celecoxib and naproxen significantly reduced plasma renin activity after furosemide administration.

"These results suggest that selective COX-2 inhibitors may be safer than nonselective nonsteroidal anti-inflammatory drugs in these patients," the authors report. "Further studies using COX-2 inhibitors for a longer period of time are required to confirm this contention."

The researchers used a short-term administration of the drugs in question to prevent any significant impairment in kidney function. As a result, the study does not offer information about the safety of these drugs when administered for long-term therapeutic purposes.

"In summary," say the authors, "the current study indicates that naproxen, but not celecoxib, administered during a short period of time, adversely affects renal function and the renal response to furosemide in cirrhotic patients with ascites and increased activity of the renin-angiotensin system."

David Greenberg | EurekAlert!
Further information:
http://www.interscience.wiley.com/journal/hepatology

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Corporate coworking as a driver of innovation

22.11.2017 | Business and Finance

PPPL scientists deliver new high-resolution diagnostic to national laser facility

22.11.2017 | Physics and Astronomy

Quantum optics allows us to abandon expensive lasers in spectroscopy

22.11.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>